Clinical Trial: Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794514) titled 'Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD' on Aug. 25.

Brief Summary: This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT. Ruxolitinib and belumosudil are both effective for cGVHD, but no head-to-head comparison specifically in hepatic cGVHD has been reported. Two cohorts are enrolled: Cohort 1 comprises patients with steroid-refractory hepatic cGVHD without prior ruxolitinib or belumosudil exposure, randomized to receive either agent. Cohort 2 includes patients who develop new-onset hepatic cGVHD afte...